Phenotype standardization for drug-induced kidney disease
Carregando...
Citações na Scopus
134
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
MEHTA, Ravindra L.
AWDISHU, Linda
DAVENPORT, Andrew
MURRAY, Patrick T.
CERDA, Jorge
CHAKARAVARTHI, Raj
HOLDEN, Arthur L.
GOLDSTEIN, Stuart L.
Citação
KIDNEY INTERNATIONAL, v.88, n.2, p.226-234, 2015
Resumo
Drug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders. We convened a panel of international, adult and pediatric, nephrologists and pharmacists to develop standardized phenotypes for drug-induced kidney disease as part of the phenotype standardization project initiated by the International Serious Adverse Events Consortium. We propose four phenotypes of drug-induced kidney disease based on clinical presentation: acute kidney injury, glomerular, tubular, and nephrolithiasis, along with the primary and secondary clinical criteria to support the phenotype definition, and a time course based on the KDIGO/AKIN definitions of acute kidney injury, acute kidney disease, and chronic kidney disease. Establishing causality in drug-induced kidney disease is challenging and requires knowledge of the biological plausibility for the specific drug, mechanism of injury, time course, and assessment of competing risk factors. These phenotypes provide a consistent framework for clinicians, investigators, industry, and regulatory agencies to evaluate drug nephrotoxicity across various settings. We believe that this is the first step to recognizing drug-induced kidney disease and developing strategies to prevent and manage this condition.
Palavras-chave
acute kidney injury, adverse reaction, drugs, glomerulonephritis, hypersensitivity, nephrotoxicity
Referências
- Aithal GP, 2011, CLIN PHARMACOL THER, V89, P806, DOI 10.1038/clpt.2011.58
- K.D.I.G.O.K.A.K.I.W. Group, 2012, KIDNEY INT, V2, P1
- Koyner JL, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-105
- McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297
- Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x
- Moffett BS, 2011, CLIN J AM SOC NEPHRO, V6, P856, DOI 10.2215/CJN.08110910
- NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
- Park YH, 2005, PEDIATR NEPHROL, V20, P1126, DOI 10.1007/s00467-005-1915-8
- Selby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911